The global vascular access device market is anticipated to rise from USD 5.6 billion in 2023 to USD 7.9 billion by 2028, with a CAGR of 7.0%. Major contributors to this growth include rising government funding for modern medical devices and the growing prevalence of lifestyle diseases. Despite this, the market may encounter barriers due to a limited pool of skilled professionals.

Download PDF Brochure

Browse in-depth TOC on "Vascular Access Device Market"

69 - Tables

40 - Figures

141 – Pages

The central vascular access device segment is accounted for largest share of the market during the forecast period

On the basis of type, central vascular access device market comprises peripheral access device, central vascular access device, and accessories segment. In 2022, the central vascular access device segment accounted the largest share of the global vascular access device market. This attributed can be due to the extensive usage of central vascular access device in chemotherapy and in the treatment of cardiovascular disorders (CVD) and chronic kidney disorders (CKD).

The drug administration segment accounted for the largest share of the market during the forecast period.

On the basis of application, vascular access device market is bifurcated into segments including drug administration, fluid and nutrition administration, blood transfusion, and diagnostic & testing. In 2022, drug administration hold the largest share of the vascular access device market. Factors include high usage of vascular access device for drug administration, mainly for the treatment of infections and cancer are driving the market growth.

The hospitals segment accounted for the largest share of the market in 2022

On the basis of end users, vascular access device market is categorized into hospitals, clinics & ambulatory centers, and other end users (nursing homes, laboratories, diagnostic & imaging centers, and home healthcare agencies). In 2022, the hospitals segment hold the largest share. The dominance of this segment can be attributed to several significant factors. These factors include majority of vascular procedures are performed in hospital settings. Also, emergency care in hospitals needs VADs for blood transfusion and administration of different drugs.

Request Sample Pages

North America to witness significant growth in the vascular access device industry from 2023 to 2028

On the basis of region, the global vascular access device market is segmented into-North America, Europe, Asia Pacific, and Rest of the World. In 2023, North America projected to lead market share of the vascular access device market. This can be attributed to the region benefits from the presence of key players, a supportive reimbursement framework, and significant government investments in cutting-edge medical devices.

Key Market Players:

The prominent players in this market are Becton, Dickinson and Company (US), ICU Medical, Inc. (US), Teleflex Incorporated (US), B. Braun SE (Germany), AngioDynamics, Inc. (US), Terumo Corporation (Japan), Nipro Medical Corporation (Japan), Medtronic (Ireland), Amecath (Egypt),Romsons (India), PRODIMED (France),Cook Medical (US), Access Vascular, Inc. (US), Medical Components, Inc. (US), Vygon (France), 3M (US), Argon Medical Devices (US), Guangdong Baihe Medical Technology Co., Ltd. (China), pfm medical (Germany), Medi-Tech Devices Pvt Ltd (India), Medline Industries, LP (US), Kimal (UK), Deltamed (Italy), Newtech Medical Devices (India) and Shanghai Puyi Medical Instruments Co., Ltd (China).

Recent Developments:

• In June 2023, Teleflex Incorporated (US) has been awarded two group purchasing agreements with Premier, Inc. The new agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex's Central Venous and Arterial Vascular Access products.
• In June 2022, Teleflex Incorporated (US) launched an Arrow Pressure Injectable Midline Catheter in Australia and New Zealand. The addition of the pressure injectable catheter further enhances the Midline portfolio to meet the expanded needs of clinicians and is designed to improve patient safety.
• In January 2022, ICU Medical, Inc. (US) completed its acquisition of Smiths Medical (US) from Smiths Group plc. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical's existing businesses, the combined companies establish a leading infusion therapy company with estimated pro forma combined revenues of approximately USD 2.5 billion.
• In July 2021, Becton, Dickinson and Company (US) acquired Velano Vascular (US). Velano Vascular needle-free technology enables high-quality blood draws from existing peripheral intravenous catheter (PIVC) lines. This acquisition can now enable health care providers to help eliminate multiple needlesticks for blood sample collection, reducing the pain and discomfort from the process while delivering quality outcomes and increased patient satisfaction.

Vascular Access Device Market Advantages:

• Improved Patient Outcomes: VADs enable precise administration of medications and fluids, ensuring accurate dosing and reducing the risk of medication errors. They also facilitate easier blood sampling, leading to timely diagnostics and appropriate treatment adjustments, ultimately improving patient outcomes.
• Minimizes Discomfort and Trauma: VADs reduce the need for repeated needle sticks and peripheral intravenous (IV) lines, minimizing patient discomfort and trauma. Central venous access devices, such as PICCs (Peripherally Inserted Central Catheters) and implantable ports, provide a stable, long-term access solution that is less invasive than conventional methods.
• Reduced Healthcare Costs: VADs reduce the frequency of venipunctures and peripheral IV insertions, decreasing the time and resources required for intravenous therapy and blood sampling. This leads to cost savings for healthcare facilities, increased staff efficiency, and improved patient throughput.
• Versatility and Flexibility: VADs come in various types and sizes, allowing healthcare providers to choose the most suitable device based on patient needs and medical requirements. This versatility ensures that vascular access can be established for patients with various conditions, including those needing long-term therapy.
• Facilitates Home Healthcare: VADs that are easy to use and maintain enable patients to receive necessary treatments in the comfort of their homes, reducing hospital stays and promoting patient independence. This is particularly beneficial for patients requiring prolonged infusion therapies.
• Enhanced Infection Control: VADs, especially those with antimicrobial coatings, contribute to better infection control by reducing the risk of bloodstream infections related to catheter use. This is critical in high-risk patients, such as those with compromised immune systems.
• Real-time Monitoring and Integration: Advancements in VAD technology enable the integration of smart sensors, allowing real-time monitoring of patient vitals and catheter performance. This data can be seamlessly integrated into electronic health records, facilitating data-driven decision-making and improving patient safety.
• Streamlined Workflows: VADs simplify the process of vascular access, enabling healthcare providers to focus on patient care rather than time-consuming insertion procedures. This can lead to increased efficiency and reduced wait times for patients in busy clinical settings.
• Greater Patient Satisfaction: The use of VADs, particularly less invasive and more comfortable options, leads to higher patient satisfaction due to reduced pain, ease of use, and the ability to receive treatments in non-clinical environments.

In conclusion, the Vascular Access Device market's advantages encompass improved patient outcomes, reduced discomfort, cost savings, flexibility, infection control, remote monitoring, streamlined workflows, and enhanced patient satisfaction. As technology continues to advance, the potential benefits of VADs are likely to increase further, making them indispensable tools in modern healthcare.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: [email protected]

Visit Our Website: https://www.marketsandmarkets.com/